Drugmaker tears up guidance after severing contentious ties with Philidor
Canadian drugmaker under siege for reliance on debt and price increases
Insurer seeks to deflect activist pressure with $400m in savings
With global steel demand shrinking, impact of price collapse on the biggest producer will be clear
Short seller’s allegation of accounting fraud deflates drugmaker’s share price
Are the pharma’s bright sparks flying too close to the sun?
Are hedge fund ‘two and 20’ fees justified for failing to beat market?
Bullion bull John Paulson trims his fund’s shares in ETF as gold price sinks
Paulson & Co and Och-Ziff build up shareholdings
Real estate assets are once again appealing to conservative institutional buyers
Bill Gross has been reunited with a bond mandate he ran at Pimco
Donation is largest to an Ivy League institution
Drugmaker moves ahead with fundraising after being outbid by Endo
Bid for US drugmaker tops lower offer from Valeant
Large bets on AbbVie’s deal for Shire along with Fannie Mae and Freddie Mac payouts go wrong
Losses as AbbVie’s £32bn deal for Dublin group is left teetering
The private equity investor is upbeat despite knocks during the global crisis
International Edition